Literature DB >> 3926733

Patterns of failure in carcinoma of the nasopharynx: I. Failure at the primary site.

B Vikram, U B Mishra, E W Strong, S Manolatos.   

Abstract

Between 1970 and 1980, we treated 107 previously untreated patients with biopsy proven carcinoma of the nasopharynx by megavoltage external radiation therapy to the primary site, base of the skull and both sides of the neck. Fifty-three percent of the patients had T4 primaries and 87% had Stage IV disease. The histology was poorly differentiated, undifferentiated or anaplastic carcinoma in 81% of the patients, and well differentiated or moderately well differentiated epidermoid carcinoma in 19%. The dose of irradiation to the primary site ranged from 5700 to 7700 rad. Fifty-five patients have suffered relapse of the cancer, 33 of whom (60%) relapsed at the primary site. Seventy-two percent of the relapses at the primary site appeared within two years after treatment and 91 percent within 3 years. Median survival following relapse at the primary site was 10 months. Those patients who received a dose to the primary between 5700 and 6700 rad had a lower rate of local control than those who received a dose between 6700 and 7700 rad. However, regardless of the dose, those patients whose radiation therapy was interrupted (for whatever reason) for a total of three weeks or longer had poorer local control than those patients whose treatment was not so interrupted. The highest rate of local control (84%) was observed in those patients who did not have such interruptions and received a dose of 6700-7700 rad to the primary. Improved local control with the higher doses was especially striking for T4 primaries, suggesting a dose-response relationship. The local control rate did not appear to be significantly influenced by age, sex, birthplace or histology. These data suggest that a high rate of local control is possible in carcinoma of the nasopharynx, even with T4 disease, if a sufficiently high dose of radiation therapy is delivered without undue interruptions.

Entities:  

Mesh:

Year:  1985        PMID: 3926733     DOI: 10.1016/0360-3016(85)90332-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Simultaneous integrated boost intensity-modulated radiotherapy (SIB‑IMRT) in nasopharyngeal cancer.

Authors:  Evangelia Peponi; Christoph Glanzmann; Guntram Kunz; Christoph Renner; Katja Tomuschat; Gabriela Studer
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

2.  On the radiobiological impact of metal artifacts in head-and-neck IMRT in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP).

Authors:  Yusung Kim; Wolfgang A Tomé
Journal:  Med Biol Eng Comput       Date:  2007-06-16       Impact factor: 2.602

3.  Radiation therapy combined with (or without) cisplatin-based chemotherapy for patients with nasopharyngeal cancer: 15-years experience of a single institution in Korea.

Authors:  Yeon-Sil Kim; Bum-Soo Kim; So-Lyoung Jung; Yeon-Soo Lee; Min-Sik Kim; Dong-Il Sun; Eun-Jung Yoo; Seong-Kwon Mun; Sei-Chul Yoon; Su-Mi Chung; Hoon-Kyo Kim; Seung-Ho Jo; Jin-Hyoung Kang
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

4.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

5.  Preliminary results of photodynamic therapy for recurrent nasopharyngeal carcinoma.

Authors:  M C Tong; C A van Hasselt; J K Woo
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

6.  Radiation therapy for early glottic carcinoma (T1N0M0). The adverse effect of treatment interruption.

Authors:  M Chatani; Y Matayoshi; N Masaki; T Teshima; T Inoue
Journal:  Strahlenther Onkol       Date:  1997-10       Impact factor: 3.621

7.  Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial.

Authors:  Richard L Bakst; Nancy Lee; David G Pfister; Michael J Zelefsky; Margie A Hunt; Dennis H Kraus; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-03       Impact factor: 7.038

8.  Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.

Authors:  Shaojun Lin; Jiade Jay Lu; Lu Han; Qisong Chen; Jianji Pan
Journal:  BMC Cancer       Date:  2010-02-10       Impact factor: 4.430

Review 9.  Contribution of radiotherapy to function preservation and cancer outcome in primary treatment of nasopharyngeal carcinoma.

Authors:  Anne W M Lee
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

Review 10.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.